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TOAC,1) the stable free radical 2,2,6,6-tetramethylpiperi-
dine-N-oxyl-4-amino-4-carboxylic acid,2) acylated at the
amine function with the tert-butyloxycarbonyl group (Boc-
TOAC), was the first protected spin-labeled amino acid deriv-
ative successfully introduced3,4) for labeling peptides through
the solid phase method.5,6) However, due to partial decompo-
sition3,7) of the nitroxide moiety during the repeated trifluo-
roacetic acid (TFA) treatments necessary for Boc group5)
removal, labeling with this paramagnetic marker was re-
stricted to the N-terminal position of the sequence. To over-
come this shortcoming, the 9-fluorenylmethyloxycarbonyl
(Fmoc) group6) was used for protection of the amine func-
tion. Moreover, the conjugation of both Fmoc (for peptide
chain elongation) and Boc (for peptide cleavage from the
resin) chemistries allowed us to propose a procedure for
TOAC insertion at any internal position of a peptide se-
quence.8)
Since its use for the synthesis of spin labeled peptides was
first described, this Ca-tetra-substituted cyclic a-amino acid
was employed in a great variety of investigations. For in-
stance, the first example of a labeled peptide hormone (a-
melanocyte stimulating hormone) that retained full biological
activity was recently reported.9) Furthermore, a large sam-
pling of mono- or doubly-labeled model peptides have been
studied in terms of structural features.10—14)
As a further development in our research on spin labeled
amino acids, here we describe the convenience of using the
b-amino acid derivative 2,2,5,5-tetramethylpyrrolidine-N-
oxyl-3-amino-4-carboxylic acid (POAC), protected with the
Fmoc group, for peptide labeling. Besides the inherent inter-
est in using this alternative spin label for a broad range of
chemical and biochemical purposes, an additional objective
for introducing POAC in peptide chemistry is to overcome
the serious difficulty in coupling the subsequent amino acid
residue after TOAC incorporation.8) This is due to the very
low nucleophilicity of its amine function when bound to a
peptide sequence (pKa,6)
3,4) which can be overcome when a
more efficient coupling procedure is applied.8) In contrast,
the amine function linked to the POAC pyrrolidine b-carbon
should confer higher nucleophilicity than that in TOAC, fa-
cilitating the coupling reaction during peptide synthesis. The
steps for POAC (3) synthesis are shown in Fig. 1 and have
been described in detail elsewhere.2,15)
Owing to the presence of two asymmetric carbons in
POAC’s b-cyclic structure, its synthesis yields a racemic
mixture. Crystals suitable for X-ray diffraction were crystals
obtained by slow evaporation from an ethanol-water solution.
Single crystal structure determination showed that a trans
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The stable free radical 2,2,6,6-tetramethylpiperidine-N-oxyl-4-amino-4-carboxylic acid (TOAC) is the only
spin labeled amino acid that has been used to date to successfully label peptide sequences for structural studies.
However, severe difficulty in coupling the subsequent amino acid has been the most serious shortcoming of this
paramagnetic marker. This problem stems from the low nucleophilicity of TOAC’s amine group towards the acy-
lation reaction during peptide chain elongation. The present report introduces the alternative b-amino acid
2,2,5,5-tetramethylpyrrolidine-N-oxyl-3-amino-4-carboxylic acid (POAC), potentially useful in peptide and pro-
tein chemistry. Investigations aimed at addressing the stereochemistry of this cyclic molecule through X-ray dif-
fraction measurements of crystalline and bulk samples revealed that it consists only of the trans conformer. The
9-fluorenylmethyloxycarbonyl group (Fmoc) was chosen for temporary protection of the POAC amine function,
allowing insertion of the probe at any position in a peptide sequence. The vasoactive octapeptide angiotensin II
(AII, DRVYIHPF) was synthesized by replacing Pro7 with POAC. The reaction of Fmoc-POAC with the peptidyl-
resin occurred smoothly, and the coupling of the subsequent amino acid showed a much faster reaction when
compared with TOAC. POAC7-AII was obtained in good yield, demonstrating that, in addition to TOAC, POAC
is a convenient amino acid for the synthesis of spin labeled peptide analogues. The present findings open the pos-
sibility of a wide range of chemical and biological applications for this novel b-amino acid derivative, including
structural investigations involving its differentiated bend-inducing characteristics.
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Fig. 1. Scheme of the Synthesis of the POAC Spin Label
conformer was obtained (Fig. 2).16) The presence of only one
conformer was established by X-ray powder analysis of the
bulk sample. Since both (R) and (S) isomers are obtained
during the synthesis of POAC, work is in progress aimed at
complementing the stereochemical analysis. For this pur-
pose, we are making use of different standard procedures in
order to achieve stereospecific isolation and synthesis.
The synthesis of Fmoc-POAC was carried out as previ-
ously reported,8) and yielded 380 mg of pure compound as a
bright yellow powder (see the Experimental section). The
feasibility of using Fmoc-POAC for peptide chemistry was
evaluated by substituting it for the Pro7 residue of the vasoac-
tive peptide angiotensin II (AII, DRVYIHPF). The POAC7-
AII analogue was assembled in a 0.15 mmol scale starting
from Phe-Wang resin (0.41 mmol/g) and following the Fmoc
chemistry procedure.6) Couplings were done with 2.5-fold
excess using diisopropylcarbodiimide and 1-hydroxybenzo-
triazol as activators. After POAC incorporation, the coupling
of the next amino acid residue [Fmoc-(trityl) His] occurred
smoothly in only 1 h. This result confirmed the facilitated
acylation of the subsequent amino acid residue to the POAC
amine group when compared to TOAC. In the latter case, the
recoupling procedure was repeated three times for quantita-
tive insertion of the His residue using the same experimental
conditions.8) Peptide cleavage from the resin, making use of
HF, lead to protonation of the nitroxide group. Recovery of
the electron paramagnetic resonance (EPR) signal of the
crude peptide was achieved upon treatment with 0.02 M am-
monium acetate, pH 10, for 10 h. The main peak obtained in
the analytical HPLC chromatogram of the crude material was
purified by a preparative reverse phase-HPLC column yield-
ing 29 mg of desired POAC7-AII. The characterization of the
sample was confirmed through amino acid analysis, analyti-
cal HPLC, and MALDI-MS (M1H)151132.55.
EPR spectra of POAC and POAC7-AII in aqueous solution
(pH55.0) are given in Fig. 3. Both compounds displayed
narrow lines, as expected for small molecules tumbling
freely in a non-viscous solution, but the rotational correlation
times (t)17,18) calculated for POAC and POAC7-AII (0.63
l0210 and 5.3310210 s21, respectively) reflect the fact that the
molecular weights of both compounds differed by nearly one
order of magnitude.
In conclusion, the present work introduces a second spin
labeled amino acid POAC, and demonstrates its potential for
application in peptide and protein chemistry and biochem-
istry. In addition to its usefulness in structure-biological ac-
tivity studies, it also opens the possibility for comparative
conformational investigation with proline-containing pep-
tides due to its pyrrolidine structure. Moreover, this spin
probe may be utilized in other studies, such as fluorescence
quenching19) and peptide binding to bilayer or micelles, simi-
larly to what has been done with TOAC derivatives.20) Fur-
thermore, in view of the importance of examining the
physico-chemical aspects of the interior of some macromole-
cular systems, POAC can also be used in the greatly expand-
ing field of polymer-supported procedures in either chemical
or biological areas. As an example, one may compare opti-
mization strategies of peptide synthesis methodologies. In
work done with TOAC,21,22) EPR monitoring of peptide chain
solvation throughout the resin matrix was interpreted in the
light of an alternative solvent polarity parameter.23) Research
using POAC derivatives for this and related purposes is in
progress.
Experimental
Solvents and reagents were purchased from Fluka or Aldrich and all met
ACS standards. Trifluoroacetic acid was acquired from Fluka, and the anhy-
drous hydrogen fluoride (5 l capacity cylinder) was from Merck Co.
Synthesis of Fmoc-POAC According to a previously published proce-
dure,8) 201 mg (1 mmol) of POAC in water/Na2CO3·10H2O was treated with
Fmoc-succinimidyl carbonate (dissolved in acetone), and the pH was ad-
justed (8.5—9.0). After 3 h stirring, the solution was diluted with cold water
and acidified to pH 2 with 1 N HCl. The desired product was extracted with
ethyl acetate, washed with small portions of water, and dried over anhydrous
Na2SO4 overnight. After filtration and evaporation, the product was crystal-
lized in CHCl3/petroleum ether, yielding 380 mg (90% yield) of Fmoc-
POAC as light yellow crystals. The analytical HPLC profile and FAB-mass
spectrum of this derivative are available in Supplementary Materials.
Characterization: [M1]5423; elemental analysis calculated for C24-
H27O5N2: C, 68.08; H, 6.28; N, 6.62. Found: C, 67.9; H, 6.35; N, 6.60. IR
(KBr) cm21: 3444 to 3338 (nNH and OH); ca. 3030 (nArCH); 3000—2700
(nCOOH); 1723 (nCOOH and R–O–C–O–N); 1543 (d NH and nCN); 1450
(d CH3); 1235—1150 (gem-dimethyl groups).
Crystallographic Analysis Data were collected on an Enraf-Nonius
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Fig. 2. ZORTEP Representation of POAC
Thermal ellipsoids of non-H atoms are drawn at the 50% probability level. H atoms
are at an arbitrary scale.
Fig. 3. EPR Spectra of 0.05 mM POAC (A) and POAC7-AII (B) in Aque-
ous Solution, pH 5.0
CAD4-Mach 3 diffractometer. Programs used: refinement SHELXL97;
graphical representation: ZORTEP.
Mass Spectrometry The crude peptide was analyzed either by Fast
Atom Bombardment (FAB)-Mass Spectroscopy in a CG-MS HP 5988A ap-
paratus or by Matrix Assisted Laser Desorption Ionization (MALDI) on a
Micromass Spectrometer, model TofSpec SE, using a-cyano-4-hydroxycin-
namic acid as the solid matrix.
Analytical and Semi-Prepartive RP-HPLC The purity analyses were
achieved in TFA/acetonitrile gradients using a Waters Associates HPLC sys-
tem consisting of two 510 HPLC pumps, an automated gradient controller,
Rheodyne manual injector, 486 UV detector and 746 data module. Solvent
A: 0.1% TFA/H2O and Solvent B: 60% acetonitrile/0.1% TFA/H2O with a
gradient of 5—95% of B in 30 min, at a flow rate of 1.5 ml/min. The column
employed was a Vydac C18 column (0.46325 cm, 5 mm particle size, 300 Å
pore size). The detection was at l5210 nm. For peptide purification, a
Vydac C18 semi-preparative column (2.5330 cm, 70 Å pore size, 7 mm parti-
cle size) was used with aqueous ammonium acetate, pH 5 and 60% (v/v)
acetonitrile solutions as solvents A and B, respectively. A linear gradient of
20—65% of B in 135 min was applied.
EPR Studies EPR measurements were carried out at 9.5 GHz in a
Bruker ER 200 spectrometer at room temperature (2262 °C) using flat
quartz cells. Labeled peptidyl-resins were pre-swollen overnight in the sol-
vent under study before running the spectra. The magnetic field was modu-
lated with amplitudes less than one-fifth of the line widths, and the mi-
crowave power was 5 mW to avoid saturation effects.
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